T-cell/Histiocyte-rich Large B-cell Lmphoma in Pediatric Patients: a Reported Case of a 16-year-old Patient in Clinical Haematology Department of the University Teaching Hospital of Yopougon (Abidjan-Ivory Coast)

T-cell/Histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare pathology, uncommon in children population and the few cases reported, had wide range clinical presentations, including advanced stage, extranodal involvement and bad prognosis. Authors report a case of a 16-year-old male patient with no medical history, who presented a single left axillary adenopathy. T-cell/Histiocyte-rich large B-cell lymphoma was diagnosed by immunohistochemistry and was classified good prognosis. A RCHOP-based chemotherapy was performed with good progress. Authors hope to contribute to the literature on THRLBCL and draw the attention of practitioners to its occurrence in the pediatric population

T-cell/Histiocyte-rich Large B-cell Lmphoma in Pediatric Patients: a Reported Case of a 16-year-old Patient in Clinical Haematology Department of the University Teaching Hospital of Yopougon (Abidjan-Ivory Coast)

T-cell/Histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare pathology, uncommon in children population and the few cases reported, had wide range clinical presentations, including advanced stage, extranodal involvement and bad prognosis. Authors report a case of a 16-year-old male patient with no medical history, who presented a single left axillary adenopathy. T-cell/Histiocyte-rich large B-cell lymphoma was diagnosed by immunohistochemistry and was classified good prognosis. A RCHOP-based chemotherapy was performed with good progress. Authors hope to contribute to the literature on THRLBCL and draw the attention of practitioners to its occurrence in the pediatric population

T-cell/Histiocyte-rich Large B-cell Lymphoma in an Adolescent from Abidjan-Ivory Coast: Case Report

T-cell/Histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare pathology, uncommon in the children population, and the few cases reported had a wide range of clinical presentations, including advanced stage, extranodal involvement, and bad prognosis. The authors report a case of a 16-year-old male patient with no medical history, who presented a single left axillary adenopathy. T-cell/Histiocyte-rich large B-cell lymphoma was diagnosed by immunohistochemistry and was classified good prognosis. RCHOP-based chemotherapy was performed with good progress. The authors hope to contribute to the literature on THRLBCL and draw the attention of practitioners to its occurrence in the pediatric population

Evolutionary profile of patients with hemoglobin SC disease regularly followed in Côte d'Ivoire

Background: West Africa is recognized as the elective focus of hemoglobin C. The S and C combination in the same patient gives a major sickle cell syndrome. In our country, very few series dealing with the evolutionary features of this SC form have been published contrary to the homozygous SS form. The aim of this study was to describe the evolutionary profile of double heterozygous SC sickle cell patients.Methods: This was a retrospective and prospective study with descriptive and analytical purpose of 174 SC sickle cell patients.Results: The median age was 26 years with extremes of 6 years and 57 years. 96% of patients had less than 4 vaso-occlusive seizures per year. The evolutionary complications were mainly ischemic (56.30%) and infectious (39.10%). Among ischemic complications, sickle cell retinopathies and aseptic osteonecrosis are the most common with 59.20% and 31.63% respectively. Infectious complications were dominated by ENT (36.76%) and osteoarticular (35.29%) infections. Only age had an influence on the occurrence of ischemic complications (p = 0.0001). The probability of survival at 5 years was 99.38% and that at 20 years was 91.57%. The overall survival was not influenced by evolutionary complications.Conclusions: Infectious and ischemic evolutionary complications show the importance of vaccination and an early screening program

Un Cas de Lupus Erythemateux Dissemine (LED) Revele par une Anemie Chronique au Service d’hematologie Clinique du CHU de Yopougon

The authors report one case of systemic lupus erythematosus revealed by chronic anemia. This was a 29-year-old patient with long-term fever, chronic skin and joint lesions with isolated hypochrome microcytic haemolytic anemia on the hemogram. The diagnosis of SLE was made three years after the onset of symptomatology based on seven of the American Rheumatology Association's (ARA) criteria out of 11, including positive immunological status (antinuclear antibodies and native DNA). This observation shows the interest of evoking SLE, while looking for signs in a young woman with multiple and varied symptoms with signs of skin, kidney, osteoarticular and hematological disorders.Les auteurs rapportent un cas de lupus érythémateux disséminé révélé par une anémie chronique. IL s’agissait d’une patiente de 29 ans présentant une fièvre au long cours, des lésions cutanées et articulaires d’évolution chronique avec à l’hémogramme une anémie hémolytique isolée hypochrome microcytaire. Le diagnostic de LED a été retenu trois années après le début de la symptomatologie devant sept critères sur 11 de L’American Rheumatology Association (ARA) dont le bilan immunologique positif (anticorps antinucléaires et DNA natif). Cette observation montre l’intérêt d’évoquer le LED, tout en recherchant les signes chez une femme jeune présentant une symptomatologie multiple et variée avec les signes d’atteintes cutanée, rénale, ostéo-articulaire et hématologique

Subclinical Cardiac Dysfunction Is Associated With Extracardiac Organ Damages

Background: Several studies conducted in America or Europe have described major cardiac remodeling and diastolic dysfunction in patients with sickle cell disease (SCD). We aimed at assessing cardiac involvement in SCD in sub-Saharan Africa where SCD is the most prevalent.Methods: In Cameroon, Mali and Senegal, SCD patients and healthy controls of the CADRE study underwent transthoracic echocardiography if aged ≥10 years. The comparison of clinical and echocardiographic features between patients and controls, and the associations between echocardiographic features and the vascular complications of SCD were assessed.Results: 612 SCD patients (483 SS or Sβ0, 99 SC, and 19 Sβ+) and 149 controls were included. The prevalence of dyspnea and congestive heart failure was low and did not differ significantly between patients and controls. While left ventricular ejection fraction did not differ between controls and patients, left and right cardiac chambers were homogeneously more dilated and hypertrophic in patients compared to controls and systemic vascular resistances were lower (p < 0.001 for all comparisons). Three hundred and forty nine SCD patients had extra-cardiac organ damages (stroke, leg ulcer, priapism, microalbuminuria or osteonecrosis). Increased left ventricular mass index, cardiac dilatation, cardiac output, and decreased systemic vascular resistances were associated with a history of at least one SCD-related organ damage after adjustment for confounders.Conclusions: Cardiac dilatation, cardiac output, left ventricular hypertrophy, and systemic vascular resistance are associated with extracardiac SCD complications in patients from sub-Saharan Africa despite a low prevalence of clinical heart failure. The prognostic value of cardiac subclinical involvement in SCD patients deserves further studies

The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance

INTRODUCTION Investment in Africa over the past year with regard to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequencing has led to a massive increase in the number of sequences, which, to date, exceeds 100,000 sequences generated to track the pandemic on the continent. These sequences have profoundly affected how public health officials in Africa have navigated the COVID-19 pandemic. RATIONALE We demonstrate how the first 100,000 SARS-CoV-2 sequences from Africa have helped monitor the epidemic on the continent, how genomic surveillance expanded over the course of the pandemic, and how we adapted our sequencing methods to deal with an evolving virus. Finally, we also examine how viral lineages have spread across the continent in a phylogeographic framework to gain insights into the underlying temporal and spatial transmission dynamics for several variants of concern (VOCs). RESULTS Our results indicate that the number of countries in Africa that can sequence the virus within their own borders is growing and that this is coupled with a shorter turnaround time from the time of sampling to sequence submission. Ongoing evolution necessitated the continual updating of primer sets, and, as a result, eight primer sets were designed in tandem with viral evolution and used to ensure effective sequencing of the virus. The pandemic unfolded through multiple waves of infection that were each driven by distinct genetic lineages, with B.1-like ancestral strains associated with the first pandemic wave of infections in 2020. Successive waves on the continent were fueled by different VOCs, with Alpha and Beta cocirculating in distinct spatial patterns during the second wave and Delta and Omicron affecting the whole continent during the third and fourth waves, respectively. Phylogeographic reconstruction points toward distinct differences in viral importation and exportation patterns associated with the Alpha, Beta, Delta, and Omicron variants and subvariants, when considering both Africa versus the rest of the world and viral dissemination within the continent. Our epidemiological and phylogenetic inferences therefore underscore the heterogeneous nature of the pandemic on the continent and highlight key insights and challenges, for instance, recognizing the limitations of low testing proportions. We also highlight the early warning capacity that genomic surveillance in Africa has had for the rest of the world with the detection of new lineages and variants, the most recent being the characterization of various Omicron subvariants. CONCLUSION Sustained investment for diagnostics and genomic surveillance in Africa is needed as the virus continues to evolve. This is important not only to help combat SARS-CoV-2 on the continent but also because it can be used as a platform to help address the many emerging and reemerging infectious disease threats in Africa. In particular, capacity building for local sequencing within countries or within the continent should be prioritized because this is generally associated with shorter turnaround times, providing the most benefit to local public health authorities tasked with pandemic response and mitigation and allowing for the fastest reaction to localized outbreaks. These investments are crucial for pandemic preparedness and response and will serve the health of the continent well into the 21st century

Results of chemotherapy in the treatment of chronic lymphoid leukemia in Black Africa: Experience of Côte d’Ivoire

Background: The treatment of chronic lymphoid leukemia currently uses news drugs which are more expensive in our countries. Its why, the results of chemotherapy remains a challenge in our sector. Aims: To evaluate the place of polychemotherapy in the treatment of chronic lymphoid leukemia in black Africa. Methods: It was a prospective, descriptive, analytic and non-comparative study, concerning the records of patients with chronic lymphoid leukemia treated and followed at the department of clinical hematology in Abidjan. Results: We included 56 patients. The average age was 62 years with extremes of 38 and 84 years. The sex ratio was 0.8 in favor of female. The clinical signs noted a tumor syndrome among which splenomegaly, classified stage III (46, 43%) and adenopathy (64, 29%). Biologically, we observed a blood lymphocytosis (50%), an anemia (39.29%) and a thrombocytopenia (62.50%). The majority of patients were classified stage A of BINET (51.79%). The COP protocol (44.64%) and the monochemotherapy with chlorambucil (39.29%) were the most used. The therapeutic response of polychemotherapy was low (12.5%) compared to 35, 71% for monochemotherapy (p = 0.0001) with overall survival significantly better in monochemotherapy. The outcome of patients used polychemotherapy were more adverse that of patients used chlorambucil alone (p = 0,003). The overall probability of survival at 12 months was 90, 9% for patients who used monochemotherapy and 63, 4% for polychemotherapy. Conclusion: Polychemotherapy in chronic lymphoid leukemia of black African has an adverse therapeutic response hence the interest of using new therapeutic possibilities